Submissions from 2026
Patient-reported outcomes with acasunlimab monotherapy and in combination with pembrolizumab: Results from a phase II study of PD-L1+ mNSCLC, J. G. Aerts, B. Besse, W. Theelen, D. M. Kowalski, G. Quere, Shirish M. Gadgeel, X. Zhou, Y. Zhou, M. J. Chisamore, M. Holst Mørch, A. Chekalova, and V. Joish
Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC, J. G. Aerts, L. Paz-Ares, B. Besse, C. F. A Helissey, A. Araújo, D. M. Kowalski, G. Quere, J. C. Benitez, F. Guisier, W. Theelen, F. Cappuzzo, Shirish M. Gadgeel, T. C. Wehler, M. J. Chisamore, T. Mark, Y. Zhou, T. J. Ong, and E. Felip
Low -neurovirulence wild-type Zika virus strains induce durable tumor regression and survival benefit in patient-derived glioblastoma models, Parvez Akhtar, Samuel Zwernik, Deb Donohoe, Stephen Whitehead, and Richard Rovin
A Novel Epithelial Tumor Signature Predicts Survival and Response to PD-1 Blockade in Non-Small Cell Lung Cancer, Muaath Alsufi, Jehad Yasin, Muthafar Alsufi, Osama Younis, Amro Assayed, and Fawzi Abu Rous
Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast Cancer: Alliance A011104/ACRIN 6694, I. Bedrosian, K. Ballman, L. M. McCall, C. E. Comstock, G. W. Unzeitig, T. Yen, A. Weiss, B. G. Haffty, Jessica M. Bensenhaver, S. M. DeSnyder, J. J. Liu, A. H. Partridge, L. A. Carey, and K. K. Hunt
Influence of Ptcy on Lymphopenia Following Allogeneic Hematopoietic Stem Cell Transplantation, Yasmeen Berry, Alec McKheen, Zachary Neme, Mahmoud Alhourani, Josephine Emole, Muneer H. Abidi, Edward Peres, Asif Alavi, and Shatha Farhan
Therapeutic Implications of Concurrent ESR1 and PI3K Pathway Mutations in HR+/HER2-Metastatic Breast Cancer, Kimberly Boldig, Sunita Ghosh, and Vrushali Dabak
Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20, Toni K. Choueiri, Jaime R. Merchan, Amita Patnaik, Alexandra Drakaki, Brian I. Rini, Sun Young Rha, Jae Lyun Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra F. Shao, Se Hoon Park, Pedro C. Barata, Jianfen Chen, Ben Weeder, Hunter Cole, Deepti M. Warad, Paul G. Foster, Yinghui Guan, and Rana R. McKay
Delayed Onset of Chronic GVHD in Patients Receiving RGI-2001 Prophylaxis: A Multicenter Phase 2b Study with Comparison to CIBMTR Matched Cohort Data, Zachariah DeFilipp, Yi-Bin Chen, Hannah K. Choe, Yvonne Efebera, Ayman Saad, Shatha Farhan, Lazaros J. Lekakis, Jean A. Yared, Gary J. Schiller, Markus Y. Mapara, Amer Assal, Dana D. Lee, and Hayley Lane
Sacituzumab govitecan in combination with capecitabine for the treatment of advanced gastrointestinal cancers after progression on standard therapy, Maria Diab, Sunita Ghosh, Gazala Khan, Zaid I. Al Saheli, Ira S. Wollner, and Philip A. Philip
Advanced pancreatic adenocarcinoma outcomes in patients with DDR deficiencies outside of BRCA1/2 and PALB2, Maria Diab, Brooke Rhead, Matina Fragkogianni, Zaid I. Al Saheli, Gazala Khan, Ira S. Wollner, Parag Parikh, David S. Kwon, and Philip A. Philip
Trends in hepatocellular carcinoma (HCC) incidence and impact of hepatitis C antiviral therapy: A population-based subgroup analysis, Jahnavi Ethakota, Palak Grover, Fnu Varsha, Bipneet Singh, Danesh Kumar, and Devin B. Malik
Post-Transplant Cyclophosphamide and Urinary-Derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) As Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation: A Phase I Dose Escalation Study (PTCY2HCG3), Shatha Farhan, Edward Peres, Josephine Emole, Asif Alavi, and Muneer H. Abidi
Investigating the Influence of Genetic Background on TNBC-T Cell Interactions in TNBC Organoids and Co-Cultures, Batoul Farran, Moses Kamita, Shuk Mei Wong, Sylvester Antwi, Valerie O. Aboah, Harriet Larrious-Lartey, Jessica M. Bensenhaver, Haythem Ali, Eleonor Walker, Foster Amponsah, Josephine Nsafu, Rose Dampson, Patrick K. Akapko, and Evelyn Jiage
Global First-in-Human (FiH) Monotherapy Dose Escalation Trial of BAY2862789, a Diacylglycerol Kinase Alpha (DGKα) Selective Intra-Cellular T Cell Checkpoint Inhibitor in Solid Tumors, Ravit Geva, Ofra Maimon, Aaron Hansen, Jeong Eun Kim, Javier Garcia-Corbacho, Enriqueta Felip, Sook Hee Hong, Kyriakos Papadopoulos, Guru Sonpavde, Alexandre Desjonqueres, Yulin Li, Christoph Mancao, Jochen Schulze, Stephen Ducray, Andrea Frohwann, Lidia Sacchetto, Huijuan Su, Laura Hunt, Stefanie Reif, David A. Schaer, Helge Roider, Leila Khoja, Shirish M. Gadgeel, and Tae Min Kim
A Comparison of Clinical Features and Treatment Outcomes in Breast Cancer Leptomeningeal Metastasis between African American and Caucasian Populations: A Single Institution Experience, Bipin Ghimire, Lisa R. Rogers, and Marian Girgis
Efficacy of Systemic Therapy in HER2-Low Breast Cancer with CNS Metastases: A "Real-World" Experience, Bipin Ghimire, Lisa R. Rogers, and Marian Girgis
Flu/Mel/TBI Peripheral Blood Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide and Bortezomib (Cy2Bor3): A Pilot Study, Adnan Khan, Xuan Ma, Edward Peres, Asif Alavi, Josephine Emole, Muneer H. Abidi, and Shatha Farhan
Preclinical Evaluation of a Novel Hyperbolic NAMPT Inhibitor in Combination with Pan-RAS Targeted Therapies in Pancreatic Ductal Adenocarcinoma, Husain Y. Khan, Mohammed N. Al Hallak, Sahar F. Bannoura, Md Hafiz Uddin, Bin Bao, Mohamad W. Sukkari, Adeeb Aboukameel, Khalil Choucair, Hugo Jimenez, Grayson Barker, Callum McGrath, Ganji Purnachandra Nagaraju, Rafic Beydoun, Yang Shi, Philip A. Philip, Azeddine Atfi, Bassel El-Rayes, Ramzi M. Mohammad, Min Wu, Michael Schelle, Boris C. Pasche, and Asfar S. Azmi
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America), Christopher Lieu, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
Zidesamtinib in Patients with ROS1+NSCLC Previously Treated with Repotrectinib or Taletrectinib, Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish M. Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, and Adrianus J. de Langen
Supporting Staff When Patients Cry for Help: Provider Satisfaction With a Cancer-Specific Mental Health Crisis Line, Taisel Losada-Bekou, Kellie Martens, Eve DePascale, Michael Ryan, Camille Romain, and Olga Slavin-Spenny
Fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma (Mel): Subgroup analyses by blinded independent central review (BICR), Meredith McKean, Amy M. Weise, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Janice Mehnert, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Jayakumar Mani, Fang Fang, Shuquan Chen, Jingxiao Chen, Laura Brennan, JuAn Wang, Israel Lowy, Mark Salvati, Matthew G. Fury, and Jean-Francois Pouliot
TRIB2 as a Therapeutic Vulnerability in ALK-Rearranged Non-Small Cell Lung Cancer, Jitender Monga, Sudha Sadasivan, Sang-Yoon Lee, Sharad K. Suthar, Craig Rogers, and Shirish M. Gadgeel
High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update, Sagar Munjal, Muneer H. Abidi, Jeremy Pantin, Preethi Prasad, Vicki L. Graves, W. Scott Goebel, and Erik J. Woods
Targeting BCL2 Pathway to Enhance Immunogenicity in ALK Plus NSCLC, Batkhishig Munkhjargal, Sudha M. Sadasivan, Shirish M. Gadgeel, and Amanda Pilling
58P Real-world intracranial effectiveness of sotorasib in second-line (2L) and beyond (2L+) treatment (tx) of KRAS G12C-mutated non-small cell lung cancer (NSCLC) with brain metastases (BM), E. Nadal, J. Sabari, A.-M. C. Dingemans, Shirish M. Gadgeel, J. Lee, J. J. Wolf, H.-W. Ko, R. Gupta, R. Jassim, C. Ardito-Abraham, M. A. Mesa Frias, and S. B. Goldberg
Tocilizumab Prophylaxis Following Idecabtagene Vicleucel in the Outpatient Setting in Patients with Relapsed or Refractory Multiple Myeloma, Edward Peres, Shatha Farhan, Josephine Emole, Muneer H. Abidi, Asif Alavi, and Cameron Peres
147TiP BNT326-02: A phase Ib/II trial of BNT326/YL202 (HER3 ADC) with pumitamig (PD-L1 × VEGF-A bsAb) in non-small cell lung cancer (NSCLC), A. Spira, I. V. Bulat, A. Schoenfeld, S. Popat, C. Zhou, M. Erman, A. Greystoke, Shirish M. Gadgeel, J. Rotow, R. Joshi, J. Neal, M. Wermke, S. Ochsenreither, C. K. Lee, M. Wenger, C. Trueck, N. Yang, H. Haliduola, R. Tibes, and X. Le
CXCL9, an Early Inflammatory Marker As Prognostic Indicator Following Allogeneic Stem Cell Transplantation: A Single Prospective cohort study, Swathi Srikantan, Xuan Ma, Asif Alavi, Josephine Emole, Edward Peres, Muneer H. Abidi, and Shatha Farhan
Exploring Potential Predictive Factors for Immunotherapy Response in Early-Stage TNBC: Insights from a Retrospective Analysis, Aroob Sweidan, John Sherwood, Muhammad A. Ahmed, Sakshi Bai, and Haythem Ali
Amino Acid Metabolic Reprogramming Drives Doramectin-Enhanced CD8+ T Cell Immunity and Tumor Control, Sedigheh Taghinezhad-S, Amirhossein Mohseni, Vincenzo Casolaro, Zhongwei Lv, and Dan Li
MTAP-deficient pancreatic adenocarcinoma: Clinical and molecular features, Amer Tamr, Sikander Chohan, Zainab Muslehuddin, Mohammed N. Al Hallak, Maria Diab, Gazala Khan, M. Wasif Saif, Zyad Kafri, Howard Crawford, David S. Kwon, Asfar S. Azmi, and Philip A. Philip
Targeting NAMPT Using Novel Inhibitor RPT-E-037 in Pancreatic Neuroendocrine Tumor, Md Hafiz Uddin, Husain Y. Khan, Amro Aboukameel, Sahar F. Bannoura, Irfana Muqbil, Hugo Jimenez, Filza Khan, Rafic Beydoun, Gregory Dyson, Yang Shi, Mohammed N. Al Hallack, Nitin Vaishampayan, Ibrahim Azar, Steve Kim, Eliza W. Bael, Miguel Tobon, Khalil Choucair, Walid Sukkari, Hafsa Imtiaz, Herbert Chen, Muhammad W. Saif, Anthony F. Shields, Ramzi M. Mohammad, Philip A. Philip, Bassel F. El Rayes, Min Wu, Michael Schelle, Boris Pasche, and Asfar S. Azmi
A Novel Detection Strategy for an Emerging Biomarker: MTAP Loss Detection with Circulating Tumor DNA (CtDNA), Lauren S. Welch, Radhika Gutta, Fawzi Abu Rous, Bindu R. Potugari, Sudha Sadasivan, and Shirish M. Gadgeel
First in Human Phase 1 Study of D3S-002, a Purposely Designed ERK1/2 Inhibitor, in Advanced Solid Tumors with MAPK Pathway Mutations, Yi-Long Wu, Michael Millward, Yanqiao Zhang, Matteo S. Carlino, Xian Wang, Amitesh Roy, Jun Zhang, Jun Zhao, Zhen Wang, Amy Weise, Debora Doroshow, Shaonan Wang, Zifei Fan, Rong Su, Jing Zhang, Jia Wang, Wenqian Wang, Cheng Chen, Qian Chen, Hui Wang, and Zhijian Chen
A Purposefully Designed ERK1/2 Inhibitor Achieving Low-Dose, Pulsatile Target Inhibition for Combination with D3S-001, a New-Generation KRAS G12C Inhibitor, Jing Zhang, Wenqian Wang, Zhiqiang Zheng, Xin Xiong, Shaonan Wang, Jia Wang, Zifei Fan, Hui Wang, Qian Chen, Cheng Chen, Michael Millward, Zhen Wang, Jun Zhao, Jun Zhang, Amy Weise, Rong Su, Zhi Jian Chen, and Yi-Long Wu
Submissions from 2025
Abstract A139: Evaluating knowledge and practice patterns of prostate cancer germline testing among providers within a large health system, Jamie T. Abad, Marielle Cabe, Kyle McElyea, Sunita Ghosh, and Clara Hwang
A HIDDEN FUNGAL TRIGGER: A CASE OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, Jamie T. Abad, Kashmira Wani, Luis Gonzalez Mosquera, and Jawad Sheqwara
Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3, Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M. O'Reilly, Zev A. Wainberg, and Mary L. B Peters
Impact of UGT1A1∗28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3, Maen Abdelrahim, Gazala Khan, Hassan Hatoum, Alice Zervoudakis, Farshid Dayyani, Li Zhang, Jia Li, Fiona Maxwell, Eileen M. O'Reilly, Zev A. Wainberg, and Mary L. B Peters
DECEASED DONOR BONE MARROW TRANSPLANT: FIRST EVER HUMAN CASE REPORT of SUCCESSFUL ENGRAFTMENT after INFUSION of A CRYOPRESERVED DECEASED DONOR BONE MARROW in A PATIENT with AML, Muneer Abidi, Josephine Emole, Shatha Farhan, Edward Peres, Asif Alavi, Nancy Mikulandric, Klodiana Neme, Preethi Prasad, Vicki Graves, Erik Woods, W. Scott Goebel, and Sagar Munjal
NON-INFECTIOUS SARCOID-LIKE INFLAMMATORY GRANULOMATOUS CONDITIONS (NSIGC) ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS (ICIS) FOR CANCER: UPDATED RESULTS FROM THE INTERNATIONAL ICARUS CONSORTIUM, Ayesha Aijaz, Arifa Bibi, Unaiza Zaman, Aqsa Ashraf, Jair Bar, Rachel Moskovitz Cohen, Damien Urban, Iddo Vardi, Hira Tanwir, Noha Abdel-Wahab, Mohamed Nuh, Maximilian J. Rost, Fabian Acker, Johannes Kleemann, Hannah Smith, Dwight H. Owen, Kevin Ho, Marc Machaalani, Razane El Hajj Chehade, Toni K. Choueiri, Alicia H. Darwin, Pauline Funchain, Alfred Chung Pui So, Eleni Karapanagiotou, George Santis, Maysa Vilbert, Ross D. Merkin, Kerry L. Reynolds, Roma A. Kankaria, and Douglas B. Johnson
Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients With Lung Adenocarcinoma, A. Al-Bzour, N. Al-Bzour, M. Hashki, Y. Estaitia, O. M. Younis, J. Alrawabdeh, S. Abualinin, B. Ricciuti, and Fawzi Abu Rous
Prediction of Distant Metastasis Using CT/PET-Based q Radiomics in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, N. N. Al-Bzour, A. N. Al-Bzour, M. N. Samarah, N. R. Othman, B. M. Alsarayrah, T. E. Alzaher, M. Hashki, Y. M. Alajlouni, R. A. Sawafta, O. M. Younis, J. Alrawabdeh, and Fawzi Abu Rous
Prediction of Distant Metastasis Using CT/PET-Based Radiomics in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, N. N. Al-Bzour, A. N. Al-Bzour, M. N. Samarah, N. R. Othman, B. M. Alsarayrah, T. E. Alzaher, M. Hashki, Y. M. Alajlouni, R. A. Sawafta, O. M. Younis, J. Alrawabdeh, and Fawzi Abu Rous
UNCOVERING SYSTEMIC LUPUS ERYTHEMATOSUS: A RARE PRESENTATION WITH SEVERE PANCYTOPENIA, IDIOPATHIC THROMBOCYTOPENIC PURPURA AND PERICARDIAL EFFUSION, Nour Aldaoud, Ayushi Garg, Vamsi K. Lavu, Joiven Nyongbella, and Wajahat Khan
Treatment outcomes following TME for biologically unfavorable locally advanced rectal cancer, Maryam A. Aleissa, Hussein Gharib, Amr Aref, Amer Zeni, Amer Alame, Ernesto Drelichman, and Jasneet Bhullar
XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRAS G12D inhibitor in pancreatic ductal adenocarcinoma, Mohammed N. Al Hallak, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Khalil Choucair, Eliza W. Beal, Miguel Tobon, Rafic Beydoun, Anthony F. Shields, Ramzi Mohammad, Jennifer L. Beebe-Dimmer, Philip A. Philip, Boris Pasche, and Asfar S. Azmi
Evaluating the management of severe anemia in the emergency department: A single-center analysis, Kabeer Ali, Kimberly Boldig, Carmen Smotherman, Brian Li, Jinous Saremian, Walter Quan, and Gabriela Bastidas Mora
Individual participant data meta-analysis comparing neoadjuvant to perioperative chemoimmunotherapy in early-stage non-small cell lung cancer according to PD-L1 status, Jawad Alrawabdeh, Sunita Ghosh, Shahm Raslan, Alessandro Di Federico, Biagio Ricciuti, and Fawzi Abu Rous
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM), Rodabe N. Amaria, Herbert L. Duvivier, Katy K. Tsai, Parisa Momtaz, Robert W. Galamaga, Evan P. Pisick, Bently P. Doonan, Amy M. Weise, Natalie Langr, James D. Winkler, Harish P. Dave, Jennifer Robinson Diamond, and Ryan J. Sullivan
Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM), Rodabe N. Amaria, Herbert L. Duvivier, Katy K. Tsai, Parisa Momtaz, Robert W. Galamaga, Evan P. Pisick, Bently P. Doonan, Amy M. Weise, Natalie Langr, James D. Winkler, Harish P. Dave, Jennifer Robinson Diamond, and Ryan J. Sullivan
Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC, I. Aza, M. Nagasaka, A. Azmi, T. Al Baghdadi, E. Dib, Fawzi Abu Rous, A. Qin, R. Shah, N. Vojjala, K. Goyal, G. Li, J. Quintanilha, J. Altenburg, and R. Graf
The role of artificial intelligence in colorectal cancer and polyp detection: A systematic review, Sakshi Bai, Bipneet Singh, Jahnavi Ethakota, Oboseh J. Ogedegbe, Olanipekun L. Ntukidem, Akshit Chitkara, Sindhu Rani, Danesh Kumar, JoAnn Hirth, and Devin B. Malik
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC), Pedro C. Barata, Brian Rini, Toni Choueri, Sumanta Pal, Philippe Barthelemy, Roberto Iacovelli, Bradley A. McGregor, Laurence Albiges, Javier Molina-Cerrillo, Benjamin Garmezy, Ralph Hauke, Sheela Tejwani, Arnab Basu, Helen Moon, Katy Beckermann, Moshe Ornstein, Rana McKay, Claudia Lebedinsky, Edgar E. Braendle, and Robert Motzer
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC), Pedro C. Barata, Brian Rini, Toni Choueri, Sumanta Pal, Philippe Barthelemy, Roberto Iacovelli, Bradley A. McGregor, Laurence Albiges, Javier Molina-Cerrillo, Benjamin Garmezy, Ralph Hauke, Sheela Tejwani, Arnab Basu, Helen Moon, Katy Beckermann, Moshe Ornstein, Rana McKay, Claudia Lebedinsky, Edgar E. Braendle, and Robert Motzer
Biomarker Analysis and Final Efficacy of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer, T. M. Bauer, J.-F. Martini, B. Besse, C.-C. Lin, R. A. Soo, G. J. Riely, F. Toffalorio, D. A. Shepard, S. Y. Liang, P. Hamilton, D. R. Camidge, S. Kao, R. Chiari, Shirish M. Gadgeel, E. Felip, A. T. Shaw, and B. Solomon
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide, Anne Bellon, Valentina Gambardella, Luis G. Paz-Ares, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad Akbar Bhatti, Pedro Rocha, Alice Ke, Frederic Massiere, Esteban Rodrigo Imedio, and Vito Dozio
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide, Anne Bellon, Valentina Gambardella, Luis G. Paz-Ares, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad A. Bhatti, Pedro Rocha, Alice Ke, Frederic Massiere, Esteban R. Imedio, and Vito Dozio
The Relationship Among Stage IV Triple Negative Breast Cancer and Regional Lymph Node Metastases, Jenny Bui, S. David Nathanson, Jessica Bensenhaver, Theresa Schwartz, Lindsay Petersen, Anna Lehrberg, Laura Dalla Vecchia, Kylie Springer, and Laura Susick
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations, David R. Camidge, Nicolas Girard, Shun Lu, Shirish M. Gadgeel, Kristof Cuppens, Se-Hoon Lee, Hidehito Horinouchi, Tae Min Kim, Angelo Delmonte, Elvire Pons-Tostivint, Robert M. Jotte, Nivedita Aanur, Han Coburn, Qi Jiang, Theodore S. Jennaro, Tony Navas, Yan Li, and Jonathan W. Goldman
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma, Toni K. Choueiri, Moshe C. Ornstein, Pedro C. Barata, Marc R. Matrana, Jaime R. Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Christopher Negro, Jianfen Chen, Paul G. Foster, Manish Monga, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma, Toni K. Choueiri, Moshe C. Ornstein, Pedro C. Barata, Marc R. Matrana, Jaime R. Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Christopher Negro, Jianfen Chen, Paul G. Foster, Manish Monga, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141), Toni Choueri, Moshe Ornstein, Pedro C. Barata, Marc Matrana, Jaime Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Chris Negro, Jianfen Chen, Paul Foster, Deepti Warad, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141), Toni Choueri, Moshe Ornstein, Pedro C. Barata, Marc Matrana, Jaime Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Chris Negro, Jianfen Chen, Paul Foster, Deepti Warad, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATENORTH AMERICA): NRG-GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher H. Lieu
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher Hanyoung Lieu
Fusing quality improvement and education frameworks to reduce delays in tumor genotyping at community cancer centers, Carmine Deluca, Jeremy Stapp, Chris Kriz, Jessica Massey, Thomas Loss, Zyad Kafri, Michael Beyer, John Marshall, Yuan Ying, Jonathan Treisman, and Zeeshan Ali
Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S- 531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors, Toshihiko Doi, Taroh Satoh, Noboru Yamamoto, Clara Hwang, Omid Hamid, Anthony J. Olszanski, Feng Zeng, Takayuki Katsube, Michael J. Chisamore, and Tomohiko Harada
Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+NSCLC, Alexander E. Drilon, Byoung Chul Cho, Jessica J. Lin, Benjamin J. Solomon, Chia-Chi Lin, Adrianus Johannes de Langen, Enriqueta Felip, Joel W. Neal, Stephen V. Liu, Ross A. Soo, Steven Kao, Jürgen Wolf, Geoffrey Liu, Christina S. Baik, Christophe Dooms, Misako Nagasaka, A. J. van der Wekken, D. Ross Camidge, Tatsuya Yoshida, Chien-Chung Lin, Gee-Chen Chang, Myung-Ju Ahn, Jessica R. Bauman, Shirish M. Gadgeel, Antonio Calles, Elvire Pons-Tostivint, Daniel Shao Weng Tan, Melissa Johnson, Chiara Bennati, and Gianluca Spitaleri
A systematic review of the impact of artificial intelligence in pancreatic cancer detection, Jahnavi Ethakota, Bipneet Singh, Sakshi Bai, Danesh Kumar, and Devin B. Malik
Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting, Shirish M. Gadgeel, Nima Nabavizadeh, Dax Kurbegov, Charles McDonnell III, James W. Lillard Jr., Marc Matrana, Alan Roth, Andrea Johnston, Sami Tahhan, Rami Owera, Matthew Margolis, Anuraag Kansal, Margarita Lopatin, Margaret McCusker, and Karthik V. Giridhar
Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting, Shirish M. Gadgeel, Nima Nabavizadeh, Dax Kurbegov, Charles McDonnell III, James W. Lillard Jr., Marc Matrana, Alan Roth, Andrea Johnston, Sami Tahhan, Rami Owera, Matthew Margolis, Anuraag Kansal, Margarita Lopatin, Margaret McCusker, and Karthik V. Giridhar
Real-World Study in Patients With ALK plus Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated With First-Line (1L) Lorlatinib, Shirish M. Gadgeel, L. Stansfield, P. Ramachandran, O. Emidio, A. Kotomale, N. Rifi, L. Alejandro, and D. Abrahami
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation, Valentina Gambardella, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Gonzalo Fernandez Hinojal, Jon Zugazagoitia, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad A. Bhatti, Pedro Rocha, Anna Vilalta-Lacarra, Esteban R. Imedio, Sandrine Micallef, Jonathan Wessen, Vito Dozio, Rikke F. Franzen, Anne Bellon, and Luis G. Paz-Ares
Treatment and outcomes of breast cancer with leptomeningeal disease: Real-world experience in the African American population, Bipin Ghimire, Maria Jamil, and Marian Girgis
Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience, Bipin Ghimire, Maria Jamil, Lisa R. Rogers, and Marian Girgis
Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience, Bipin Ghimire, Maria Jamil, Lisa R. Rogers, and Marian Girgis
MM-259: Impact of the International Myeloma Working Group (IMWG) SLiM Criteria on Multiple Myeloma Management: A Tertiary Care Center Experience, Dhairya Gor, Tasnim Rehman, Anju Pradeep, Sunita Ghosh, and Philip Kuriakose
Safety and Efficacy of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) for the Treatment of Sickle Cell Disease with Severe Vaso-Occlusive Crises: Results from the Ongoing Phase 1/2 Beacon Study, Ashish O. Gupta, Akshay Sharma, Haydar Frangoul, Jignesh Dalal, Julie Kanter, Asif Alavi, John F. DiPersio, Mary Eapen, Jennifer J. Jaroscak, Ernesto Ayala, Edward D. Ziga, Stacey Rifkin-Zenenberg, Alex C. Minella, Guo Chen, Yinzhong Chen, Priya S. Chockalingam, Ling Lin, Marcelyne Joseney-Antoine, Leanne Ianniello, Beth Gardner, Adam J. Hartigan, Giuseppe Ciaramella, Sunita Goyal, Amy Simon, Alexis A. Thompson, and Matthew M. Heeney
BASE EDITING FOR SICKLE CELL DISEASE: ONGOING RESULTS FROM THE BEACON STUDY EVALUATING THE SAFETY AND EFFICACY OF BEAM-101, THE FIRST BASE-EDITED AUTOLOGOUS CD34+ HSPC ONE-TIME CELL THERAPY, Ashish Gupta, Akshay Sharma, Jignesh Dalal, Julie Kanter, Ernesto Ayala, John DiPersio, Haydar Frangoul, Markus Mapara, Jennifer Jaroscak, Asif Alavi, Mary Eapen, Stacey Rifkin-Zenenberg, Edward Ziga, Elizabeth Stenger, Rabi Hanna, Tami D. John, Shanna White, Thomas S. Bowman, Yinzhong Chen, Sarah Chesler, Priya S. Chockalingam, Ling Lin, John J. Ko, Marcelyne Joseney-Antoine, Leanne Ianniello, Guo Chen, Beth Gardner, Sunita Goyal, Amy Simon, and Alexis Thompson
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study, Ashish Gupta, Akshay Sharma, Haydar Frangoul, Julie Kanter, Markus Mapara, Jignesh Dalal, Asif Alavi, Jennifer Jaroscak, Ernesto Ayala, John DiPersio, Edward D. Ziga, Mary Eapen, Stacey Rifkin-Zenenberg, Srikanth Ambati, Yinzhong Chen, Sarah Chesler, Marcelyne Joseney-Antoine, Leanne Ianniello, Bahru Habtemariam, Priya Chockalingam, Ling Lin, Sunita Goyal, Amy Simon, Alexis Thompson, and Matthew Heeney
298MO Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC, E. P. Hamilton, H. Han, N. Abuhadra, K. Kalinsky, N. P. McAndrew, A. Spira, N. Chan, K. Kelley, R. Parajuli, J. O'Shaughnessy, D. Starks, G. Wulf, Amy M. Weise, A. Chaudhry, J. S. Wang, D. L. Richardson, F. Meric-Bernstam, R. Burger, C. Bradshaw, and A. Giordano
Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4- directed dolasynthen antibody-drug conjugate, Erika P. Hamilton, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Nicholas P. McAndrew, Alexander I. Spira, Nancy Chan, David Starks, Gerburg M. Wulf, Arvind Chaudhry, Kristen Kelley, Ritesh Parajuli, Judy S. Wang, Joyce O'Shaughnessy, Amy M. Weise, Debra L. Richardson, Dario R. Roque, Renata Ferrarotto, Nora Zizlsperger, and Antonio Giordano
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Antonio Giordano, David Starks, Gerburg M. Wulf, Nicholas P. McAndrew, Joyce O'Shaughnessy, Alexander I. Spira, Nancy Chan, Kristen Kelley, Ritesh Parajuli, Amy M. Weise, Arvind Chaudhry, Judy S. Wang, Debra L. Richardson, Dario R. Roque, Funda Meric-Bernstam, Caroline Rogalski, and Erika P. Hamilton
Transcriptomic Profiling Identifies a Prognostic and Predictive Immune Signature in Patients (Pts) With Lung Squamous Cell Carcinoma (LUSC), M. K. Hashki, N. N. Al-Bzour, A. N. Al-Bzour, J. Al Rawabdeh, O. M. Younis, and Fawzi Abu Rous
CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES OF AFRICAN AMERICAN VERSUS CAUCASIAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF TRUMPET REGISTRY, Clara Hwang, James Symanowski, Neal Shore, David Russell, Pavol Kral, Dina Elsouda, Nader El-Chaar, and Lawrence Karsh
Investigating the roles of GLI transcription factors in the pancreatic cancer microenvironment, Paola Isabel, Medina Cabrera, Michael Scales, Nina G. Steele, Nicole Franks, Hannah Dear, Giulia Biffi, David Tuveson, Marina Pasca di Magliano, and Benjamin Allen
Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%, M. L. Johnson, E. Arriola, T. Kato, N. Girard, Shirish M. Gadgeel, M. Majem Tarruella, T. Newsom-Davis, M. Polaczek, X. Chen, K. Stefaniak, C. Lowery, N. Angra, G. Doherty, and M-J. Ahn
Questioning Protocols: The Case Against Routine Post-Lumpectomy Mammography for Patients with Calcifications, Christine Joliat, Jessica Bensenhaver, Ena Muhamedovic, Marcus Brown, Shermeen Rahmat, Anne Patterson, Laura Dalla Vecchia, Lindsay Petersen, Anna Lehrberg, S. David Nathanson, and Theresa Schwartz
Breaking Barriers: Enhancing Access to Genetic Testing for All Breast Cancer (BC) Patients, Christine M. Joliat, Jessica Bensenhaver, Ena Muhamedovic, Theresa Schwartz, Laura Dalla Vecchia, Laura Susick, Lindsay Petersen, and Anna Lehrberg
Vascular heterogeneity influences treatment response in pancreatic cancer, Samantha B. Kemp, William B. Sullivan, Benjamin M. Kahn, Jonathan H. Sussman, Il-Kyu Kim, Takeshi Katsuda, Sidney Mahan, Margo I. Orlen, Samuel D. Zwernik, Kailee M. G, Steele Agnieszka K, Witkiewicz Erik S, Knudsen Ben Z, and Stanger #REF! #REF!
Vascular heterogeneity influences treatment response in pancreatic cancer, Samantha B. Kemp, William B. Sullivan, Benjamin M. Kahn, Jonathan H. Sussman, Il-Kyu Kim, Takeshi Katsuda, Sidney Mahan, Margo I. Orlen, Samuel D. Zwernik, Kailee M. Hartway, Nina G. Steele, Agnieszka K. Witkiewicz, Erik S. Knudsen, and Ben Z. Stanger
NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study, Xiuning Le, Zofia Piotrowska, Alexander I. Spira, Christina S. Baik, Maria Q. Baggstrom, Gerald S. Falchook, Joel W. Neal, Shirish M. Gadgeel, Gilberto Lopes, Melissa L. Johnson, Jonathan W. Riess, Danny Nguyen, Lisa Morelli, Danieska Sandino, Steven Margossian, Vivek Upadhyay, and Fernando Santini
Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations, X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, Shirish M. Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A. J. de Langen, J. Mazieres, M. Perol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, and J. Wang
Proteogenomic characterization of antibody-drug conjugate target expression profiles in transcriptional subtypes of small cell lung cancer, Edwin Lin, Mitch Singstock, Sanad Alhushki, Sameer S. Deshmukh, Changde Cheng, Kayla Goliwas, Jessy Deshane, Abdul R. Naqash, Fawzi Abu Rous, Rajat Thawani, and Aakash Desai
Palazestrant (OP-1250) plus ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced breast cancer (ABC), N. Lin, J. Chien, C. X. Ma, J. A. Mouabbi, V. Abramson, D. A. Potter, J. Sparano, H. T. Khong, J. Chaves, A. Tan, C. A. Alemany, D. Sabanathan, Randa Loutfi, L. Sun, M. Shaw, D. Vecchio, and V. Borges
Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data, G. Lopes, J. Gainor, V. Subbiah, D. Bowles, R. Doebele, A. Mansfield, C. Baik, Shirish M. Gadgeel, G. Kalemkerian, S-H. I. Ou, C. Becerra, M. Evangelist, S. Liu, J. Melear, A. Saxena, A. Thomassen, S. Wang, and B. Besse
Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study, Gilberto Lopes, Justin F. Gainor, Vivek Subbiah, Daniel W. Bowles, Robert C. Doebele, Aaron S. Mansfield, Christina S. Baik, Shirish M. Gadgeel, Gregory P. Kalemkerian, Sai-Hong I. Ou, Carlos R. Becerra, Makenzi C. Evangelist, Stephen V. Liu, Jason M. Melear, Ashish Saxena, Amber Thomassen, Sophia Wang, and Benjamin Besse
